Alpenglow Biosciences
Steve Pemberton has a varied and extensive work experience in the medical and biotechnology industries. Steve has held senior positions in several companies, including Alpenglow Biosciences, Ultivue, Haematologic Technologies, Bionique Testing Laboratories, and Rheonix, Inc. Steve has also worked as an independent business development consultant and has experience in sales and marketing roles at Ventana Medical Systems and Abbott Laboratories. Throughout their career, Pemberton has focused on commercial development, sales, and marketing, working towards advancing technology adoption and developing new cures for various diseases.
Steve Pemberton completed their education history with a Bachelor of Science (B.S.) degree in Psychology from Arizona State University, which they obtained from 1985 to 1987. Prior to that, they attended Arizona State University from 1996 to 1997 and pursued a degree in Medical Technology. Additionally, Pemberton attended the University of Arizona from 1983 to 1985, although specific degree information is not provided. In terms of certifications, Pemberton obtained the Clinical Laboratory Scientist/Medical Technologist certification from the AMERICAN SOCIETY OF CLINICAL PATHOLOGISTS in May 1997.
This person is not in any offices
Alpenglow Biosciences
Founded in 2018, Seattle-based Alpenglow Biosciences is a privately held, early-stage life sciences company focused on accelerating drug development and improving clinical diagnostics with AI-enabled, 3D imaging technology. Our platform solution provides new spatial biology insights with greater accuracy by digitizing entire tissues while keeping samples intact for additional analysis. Alpenglow partners with pharmaceutical companies to develop better therapeutics and greater understanding of biodistribution, mechanism of action, and rank ordering of potential candidates using our patented technology. Five of the top 10 pharma companies work with Alpenglow to accelerate development timelines, gain new insights, and improve therapeutic success.